CliffBio
biologic

Neupogen

filgrastim

Loss of exclusivityFebruary 2003projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameNeupogen
Active ingredientfilgrastim
Strength300MCG/ML
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalFebruary 1991
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Neupogen patent cliff — loss of exclusivity February 2003 | CliffBio